Featured Research

from universities, journals, and other organizations

Taking The Wraps Off Drug Safety Data From Clinical Trials

Date:
March 20, 2007
Source:
Harvard School Of Public Health
Summary:
For years, pharmaceutical companies have sought to restrict public access to drug safety data collected in clinical trials on the basis that it is proprietary information, arguing that competitors could use that information in the development of their own products. However, a number of recent cases of drugs found to have dangerous side effects after coming to market, such as the anti-inflammatory drug rofecoxib (Vioxx), have raised concerns about safety data being treated as confidential.

For years, pharmaceutical companies have sought to restrict public access to drug safety data collected in clinical trials on the basis that it is proprietary information, arguing that competitors could use that information in the development of their own products. However, a number of recent cases of drugs found to have dangerous side effects after coming to market, such as the anti-inflammatory drug rofecoxib (Vioxx), have raised concerns about safety data being treated as confidential.

A new analysis by researchers at the Harvard School of Public Health (HSPH) and Brigham and Women’s Hospital (BWH) of laws and regulations governing public disclosure of clinical trial data submitted to the Food and Drug Administration (FDA) suggests changes should be made to the way the FDA implements its policy regarding the confidentiality of those data. Allowing greater access to safety data would enable researchers to independently evaluate risks, resulting in more timely risk detection.

“The Vioxx case and other drug safety cases have demonstrated the value of making these data available to researchers,” said co-author Aaron Kesselheim, M.D., Department of Pharmacoepidemiology at BWH and an attorney.

Currently, pharmaceutical manufacturers submit clinical trial data, which establish the safety and efficacy of their products, to the FDA as part of the drug application process. However, after the agency approves a New Drug Application (NDA), it does not release a full report of the safety and efficacy data. Rather, it releases a summary of the clinical data section of the NDA (called the Summary Basis of Approval), and FDA regulations allow the drug manufacturer to draft the Summary. The process reflects an understanding by the FDA that safety and efficacy information should be protected, so that competing manufacturers can’t use those data to develop generic alternatives or competing drugs.

Consumer groups have brought lawsuits against the FDA under the Freedom of Information Act to obtain safety data; these have had mixed results. Lawsuits are not an ideal vehicle for consumer groups and researchers to gain access to data, given that litigation is expensive and cases can take years to move through the legal system.

The commentary authors, Dr. Kesselheim and Michelle Mello, an associate professor of health policy and law at the HSPH, believe that making drug safety data public rarely presents a risk to a pharmaceutical company’s confidential research and development efforts. “The legal question is whether the information will give other drug companies an unfair competitive advantage,” said Mello. “But it is strange to argue that evidence that a drug is harmful will enable others to develop similar drugs.” The authors suggest that current FDA policies can and should be changed in ways that allow the scientific community access to safety data before and after an NDA is approved. They offer a number of recommendations, including:

* Placing a heavier burden of proof on companies to show competitive harm if data are released.

* Replacing the current Summary Basis of Approval with a more comprehensive public document that includes all safety data.

* Getting Congress to pass legislation requiring public disclosure of safety data if the FDA fails to take action.

“Safety data from drug clinical trials have important ramifications for public health,” said Kesselheim. “The government should do as much as it can to ensure full disclosure of the information.”

Aaron Kesselheim’s work is supported by a National Research Service Award to Brigham and Women’s Hospital. Michelle Mello’s work is supported by the Greenwall Faculty Scholars Program.

Reference: “Confidentiality Laws and Secrecy In Medical Research: Improving Public Access to Data On Drug Safety,” Aaron S. Kesselheim, Michelle M. Mello, Health Affairs, Volume 26, Number 2.


Story Source:

The above story is based on materials provided by Harvard School Of Public Health. Note: Materials may be edited for content and length.


Cite This Page:

Harvard School Of Public Health. "Taking The Wraps Off Drug Safety Data From Clinical Trials." ScienceDaily. ScienceDaily, 20 March 2007. <www.sciencedaily.com/releases/2007/03/070320082329.htm>.
Harvard School Of Public Health. (2007, March 20). Taking The Wraps Off Drug Safety Data From Clinical Trials. ScienceDaily. Retrieved April 16, 2014 from www.sciencedaily.com/releases/2007/03/070320082329.htm
Harvard School Of Public Health. "Taking The Wraps Off Drug Safety Data From Clinical Trials." ScienceDaily. www.sciencedaily.com/releases/2007/03/070320082329.htm (accessed April 16, 2014).

Share This



More Health & Medicine News

Wednesday, April 16, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Could Even Casual Marijuana Use Alter Your Brain?

Could Even Casual Marijuana Use Alter Your Brain?

Newsy (Apr. 16, 2014) A new study conducted by researchers at Northwestern and Harvard suggests even casual marijuana use can alter your brain. Video provided by Newsy
Powered by NewsLook.com
Ebola Outbreak Now Linked To 121 Deaths

Ebola Outbreak Now Linked To 121 Deaths

Newsy (Apr. 15, 2014) The ebola virus outbreak in West Africa is now linked to 121 deaths. Health officials fear the virus will continue to spread in urban areas. Video provided by Newsy
Powered by NewsLook.com
Cognitive Function: Is It All Downhill From Age 24?

Cognitive Function: Is It All Downhill From Age 24?

Newsy (Apr. 15, 2014) A new study out of Canada says cognitive motor performance begins deteriorating around age 24. Video provided by Newsy
Powered by NewsLook.com
How Mt. Everest Helped Scientists Research Diabetes

How Mt. Everest Helped Scientists Research Diabetes

Newsy (Apr. 15, 2014) British researchers were able to use Mount Everest's low altitudes to study insulin resistance. They hope to find ways to treat diabetes. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins